X4 Pharmaceuticals

112 articles with X4 Pharmaceuticals

• X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

  5/15/2018

  X4 Pharmaceuticals, today announced results from a pilot study of X4P-001-IO in combination with Opdivo® (nivolumab) in patients with clear cell renal cell carcinoma (ccRCC).

• X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab)

  5/8/2018

  Study designed to evaluate X4P-001-IO in expanded range of combination treatment settings to be presented at the Annual Meeting of the Association for Cancer Immunotherapy

• Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome

  4/24/2018

  Study aims to establish a genetic screening approach to aid in diagnosis of patients with WHIM syndrome

• X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity

  4/16/2018

  Clinical data demonstrate single agent X4P-001-IO increases immune cell infiltration and activation in the tumor microenvironment (TME)

• X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

  3/15/2018

  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.

• X4 Pharmaceuticals to Present at Cowen and Company Healthcare Conference

  3/9/2018

  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Wednesday, March 14, 2018, at 8:00 a.m. Eastern time.

• First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients With WHIM Syndrome, a Primary Immunodeficiency Disease

  12/11/2017

  The preliminary results from the study demonstrated promising activity with dose-dependent increases in neutrophil and lymphocyte counts in patients with WHIM syndrome.

• X4 Pharma: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients With WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting

  11/16/2017

  Dr. David C. Dale, MD will present the first clinical data from an on-going study of X4P-001-RD in patients with WHIM Syndrome.

• 

  Founded by Genzyme Alumni, Cambridge's X4 Pharma Scores $27M

  11/16/2017

  The company plans to use the cash to advance its two lead drug programs into the clinic.

• X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway With X4P-001-IO

  11/10/2017

  The data, primarily generated from biopsies of tumors from melanoma patients, demonstrated important changes in the tumor microenvironment.

• X4 Pharma Release: First Clinical Data From Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients With Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/3/2017

  X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T-cell Infiltration in Human Metastatic Melanoma

• X4 Pharma Release: Clinical Data for X4P-001-IO in Combination With Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma

  10/30/2017

  The data were presented at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29 in Philadelphia.

• Updated Clinical Data From Combination of X4P-001-IO and Inlyta (Axitinib) in Patients With Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/26/2017

  X4 Pharmaceuticals today announced that the American Association for Cancer Research (AACR) has published Phase 1 data from an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib), Pfizer’s VEGFR kinase inhibitor.

• X4 Pharma Release: Initial Clinical Trial Data For Combination Of X4P-001-IO And Inlyta (Axitinib) Demonstrate Encouraging Disease Control Rates And Durable Clinical Responses In Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

  9/11/2017

• X4 Pharma Release: First Data From Combination Of X4P-001-IO And Inlyta (Axitinib) In Patients With Clear Cell Renal Cell Carcinoma Will Be Presented At The European Society Of Medical Oncology 2017 Congress

  8/31/2017

• X4 Pharma Announces Rare Disease Research Collaboration With Yale

  8/2/2017

• X4 Pharma Announces Initiation Of The Phase II Expansion Of Its Phase I/II Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma

  5/25/2017

• X4 Pharma Announces Initiation Of A Phase 2/3 Clinical Study Of X4P-001-LD In Patients With WHIM Syndrome, A Rare Genetic Primary Immunodeficiency Disease

  1/30/2017

• X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma

  1/26/2017

• X4 Pharma Release: Company Appoints Dr. Sudha Parasuraman As Chief Medical Officer

  1/23/2017